Explore the Global Liver Fibrosis Treatment Market — Key Trends, Regional Growth, Top Players, and 10-Year Forecast from 2026 to 2036

Future Market Insights

Liver Fibrosis Treatment Market

Key Insight

Liver fibrosis treatment sales will rise through 2036, driven by PPAR-Alpha agonists at 35.2% of the treatment type segment in 2026. The market was valued at USD 20.28 billion in 2025 and is expected to be worth USD 65.19 billion by 2036, creating an incremental opportunity of USD 42.64 billion.

April 23, 2026

Anurag Sharma

300 Pages

Cite this Report

Liver Fibrosis Treatment Market

https://www.futuremarketinsights.com/reports/liver-fibrosis-treatment-market

License

Buy Now

Summary ToC Infographics Companies

Key Players

Bristol-Myers Squibb
Galectin Therapeutics
Genfit
Gilead Sciences
Intercept Pharmaceuticals
The Vanguard Group
Madrigal Pharmaceuticals
Merck KGaA
Novartis
SMEs
Zydus Lifesciences Ltd

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Liver Fibrosis Treatment Market

Key Players

Similar Industry Reports